Compound News and Research

RSS

TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic compound that sharply inhibits the activity of a protein that plays an important role in in the progression of breast and pancreatic cancers.

15 Jan 2015

Knocking down a single gene can help stop stress from causing infertility, miscarriage

Scientists from the University of California Berkeley have discovered that by knocking down a single gene, they can stop stress from causing female infertility and miscarriage - in rats.

14 Jan 2015

QDREC software may help find effective treatment for schistosomiasis

For decades, scientists around the world have worked to develop a treatment for schistosomiasis, a debilitating water-born parasite that affects more than 200 million people worldwide. To aid this research, Rahul Singh, professor of computer science at San Francisco State University, has developed software that solves the key challenge of quantitatively assessing the impact of a drug on the parasite.

14 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

Review shows that fish compound can help combat cardiovascular disease

A major international review of a peptide originally found in fish that could be used in the battle against cardiovascular disease has been published.

13 Jan 2015

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

A team led by scientists at The Scripps Research Institute has identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited neurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that inhibit this enzyme.

13 Jan 2015

New insight into molecular mechanism of ancient evolutionary enzyme

A team led by structural biologists at The Scripps Research Institute has taken a big step toward understanding the intricate molecular mechanism of a metabolic enzyme produced in most forms of life on Earth.

12 Jan 2015

Scientists discover potential solution to antibiotic resistance

A newly developed technique for screening microbes has led to the discovery of a powerful new antibiotic that can easily kill severe infections in mice, without causing side effects.

8 Jan 2015

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Jan 2015

LSNE's Harvey Road facility receives approval to manufacture drug product for US distribution

Lyophilization Services of New England, Inc. announced today that following an FDA Pre-Approval Inspection (PAI) in November 2014, their Harvey Road manufacturing site has received approval to manufacture commercial drug product for US distribution.

7 Jan 2015

Very small changes in blood acidity level may have detrimental impact on patients with CKD

A University of Manchester scientist has discovered that very small changes in the level of acidity in blood may have a detrimental impact on the health of patients with kidney disease.

7 Jan 2015

U-M researchers reveal key gene that may provide potential target for cancer treatment

One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth.

6 Jan 2015

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company's lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP).

5 Jan 2015

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

Cell biologists at UT Southwestern Medical Center have targeted telomeres with a small molecule called 6-thiodG that takes advantage of the cell's 'biological clock' to kill cancer cells and shrink tumor growth.

2 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.

31 Dec 2014

OncoGenex executes initial agreement with Teva to regain rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.

31 Dec 2014

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

Intriguing small molecule directs activity of key ‘clock proteins’

In research published in Nature Communications, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports intriguing findings about a small molecule that directs the activity of key "clock proteins," offering the potential to manage circadian rhythm and treat problems that are associated with its dysfunction, like sleep and anxiety disorders.

24 Dec 2014

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., announced that it has executed an agreement with Janssen Pharmaceutica NV, for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.

23 Dec 2014

Compound News and Research

TSRI scientists identify novel synthetic compound that reduces activity of a cancer-related protein

Knocking down a single gene can help stop stress from causing infertility, miscarriage

QDREC software may help find effective treatment for schistosomiasis

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Review shows that fish compound can help combat cardiovascular disease

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

New insight into molecular mechanism of ancient evolutionary enzyme

Scientists discover potential solution to antibiotic resistance

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

LSNE's Harvey Road facility receives approval to manufacture drug product for US distribution

Very small changes in blood acidity level may have detrimental impact on patients with CKD

U-M researchers reveal key gene that may provide potential target for cancer treatment

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

UT Southwestern researchers target cells' biological clock to kill cancer cells, shrink tumor growth

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

OncoGenex executes initial agreement with Teva to regain rights to custirsen

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Intriguing small molecule directs activity of key ‘clock proteins’

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News